Innocell™

Autologous Therapy for Solid Tumor Cancers

Phase 1 Clinical Study for Ovarian Cancer in 2024

Ovarian Cancer in US

  • 19,880 new cases/yr

  • 12,810 deaths/yr

  • 49.7% 5yr survival

  • SOC = surgery + 3-6 cycles of chemo

Intended Use: Innocell is expected to delay the progression of disease following or in combination with chemotherapy, immunotherapy, radiotherapy, or surgical treatment of patients with solid tumor malignancies.  

Phase 1 Study FDA Cleared to Assess the Safety and Immunogenicity of Innocell Autologous Vaccine Administered to Patients with Recurrent Epithelial Ovarian Cancer

  • Patients ≥18 years old

  • Patients with Recurrent Epithelial Ovarian Cancer